57 related articles for article (PubMed ID: 30535537)
1. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study.
Pavel M; Borson-Chazot F; Cailleux A; Hörsch D; Lahner H; Pivonello R; Tauchmanova L; Darstein C; Olsson H; Tiberg F; Ferone D
Cancer Chemother Pharmacol; 2019 Feb; 83(2):375-385. PubMed ID: 30535537
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic comparison of subcutaneous
Saltzstein D; Shore ND; Moul JW; Chu F; Concepcion R; de la Motte S; McLane JA; Atkinson S; Yang A; Crawford ED
Ther Adv Urol; 2018 Feb; 10(2):43-50. PubMed ID: 29434672
[TBL] [Abstract][Full Text] [Related]
3. Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
Trials; 2024 May; 25(1):297. PubMed ID: 38698434
[No Abstract] [Full Text] [Related]
4. Health-Related Quality of Life for Long-Acting Octreotide versus Placebo in Patients with Metastatic Midgut Neuroendocrine Tumors in the Phase 3 PROMID Trial.
Rinke A; Neary MP; Eriksson J; Hunger M; Doan T; Karli D; Arnold R
Neuroendocrinology; 2019; 109(2):141-151. PubMed ID: 30852564
[TBL] [Abstract][Full Text] [Related]
5. Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial.
Perico N; Ruggenenti P; Perna A; Caroli A; Trillini M; Sironi S; Pisani A; Riccio E; Imbriaco M; Dugo M; Morana G; Granata A; Figuera M; Gaspari F; Carrara F; Rubis N; Villa A; Gamba S; Prandini S; Cortinovis M; Remuzzi A; Remuzzi G;
PLoS Med; 2019 Apr; 16(4):e1002777. PubMed ID: 30951521
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
Bonert V; Mirocha J; Carmichael J; Yuen KCJ; Araki T; Melmed S
J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32754748
[TBL] [Abstract][Full Text] [Related]
8. Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Colao A; Bronstein MD; Brue T; De Marinis L; Fleseriu M; Guitelman M; Raverot G; Shimon I; Fleck J; Gupta P; Pedroncelli AM; Gadelha MR
Eur J Endocrinol; 2020 Jun; 182(6):583. PubMed ID: 32217809
[TBL] [Abstract][Full Text] [Related]
9. A Pituitary Society update to acromegaly management guidelines.
Fleseriu M; Biller BMK; Freda PU; Gadelha MR; Giustina A; Katznelson L; Molitch ME; Samson SL; Strasburger CJ; van der Lely AJ; Melmed S
Pituitary; 2021 Feb; 24(1):1-13. PubMed ID: 33079318
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
11. The Future of Somatostatin Receptor Ligands in Acromegaly.
Gadelha MR; Wildemberg LE; Kasuki L
J Clin Endocrinol Metab; 2022 Jan; 107(2):297-308. PubMed ID: 34618894
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).
An Z; Lei T; Duan L; Hu P; Gou Z; Zhang L; Durand-Gasselin L; Wang N; Wang Y; Gu F;
BMC Endocr Disord; 2020 May; 20(1):57. PubMed ID: 32366244
[TBL] [Abstract][Full Text] [Related]
13. Medical treatment of functional pituitary adenomas, trials and tribulations.
Capatina C; Hanzu FA; Hinojosa-Amaya JM; Fleseriu M
J Neurooncol; 2024 Jun; 168(2):197-213. PubMed ID: 38760632
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide.
Johnsson M; Pedroncelli AM; Hansson A; Tiberg F
Endocrine; 2024 Jun; 84(3):1125-1134. PubMed ID: 38421556
[TBL] [Abstract][Full Text] [Related]
15. Biocompatible strategies for peptide macrocyclisation.
He J; Ghosh P; Nitsche C
Chem Sci; 2024 Feb; 15(7):2300-2322. PubMed ID: 38362412
[TBL] [Abstract][Full Text] [Related]
16. Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults.
Caulley L; Quinn JG; Doyle MA; Alkherayf F; Metzendorf MI; Kilty S; Hunink MGM
Cochrane Database Syst Rev; 2024 Feb; 2(2):CD013561. PubMed ID: 38318883
[TBL] [Abstract][Full Text] [Related]
17. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S; Ferone D; Capdevila J; Chan JA; de Herder WW; Halperin D; Mailman J; Hellström L; Liedman H; Svedberg A; Tiberg F
Trials; 2024 Jan; 25(1):58. PubMed ID: 38229199
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
[TBL] [Abstract][Full Text] [Related]
19. New Treatments for Acromegaly in Development.
Gadelha MR; Gadelha AC; Kasuki L
J Clin Endocrinol Metab; 2024 Mar; 109(4):e1323-e1327. PubMed ID: 37757837
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
